# Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants

> **NCT02782975** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 28 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** aducanumab

## Key facts

- **NCT ID:** NCT02782975
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782975, "Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02782975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*